THE ROLE OF MONOCLONAL ANTIBODY IN THE MANAGEMENT OF PROSTATE ADENOCARCINOMA

Abstract

No AccessJournal of UrologyFestschrift in Honor of 85th Birthday of Dr. William Wallace Scott, Sr1 Dec 1998THE ROLE OF MONOCLONAL ANTIBODY IN THE MANAGEMENT OF PROSTATE ADENOCARCINOMA JOHN H. TEXTER and CHARLES E. NEAL JOHN H. TEXTERJOHN H. TEXTER More articles by this author and CHARLES E. NEALCHARLES E. NEAL More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)62197-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: A study using monoclonal antibody ProstaScint* was conducted to determine the role of radioscintigraphy for evaluation of patients with adenocarcinoma of the prostate. Previous evaluations determining sensitivity and toxicity for this agent were conducted in a multicenter study. Materials and Methods: ProstaScint scans were used for preoperative staging in patients presumed to be candidates for total prostatectomy and a subsequent study was performed for the detection and localization of recurrent prostate cancer following definitive therapy. Results: The monoclonal antibody scan detected localized recurrent cancer in 43 patients who were possible candidates for external beam radiation therapy. Conclusions: The monoclonal antibody conjugate ProstaScint provides additional information in detection and localization of recurrent prostate cancer and would be helpful in the selection of patients for subsequent external beam radiation therapy. References 1 : Monoclonal Antibodies Hybridomas: A New Dimension in Biological Analysis. New York: Plenum Press1982. Google Scholar 2 : Radioimmunoscintigraphy of prostate cancer. Sem. Nucl. Med.1989; 14: 309. Google Scholar 3 : Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res1987; 7: 927. Google Scholar 4 : Monoclonal antibodies in cancer treatment. Res. Staff Phys1994; 40: 13. Google Scholar 5 : Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Sem. Urol.1992; 10: 45. Medline, Google Scholar 6 : Advances in imaging prostate cancer. Adv. Prostate Cancer1997; 1: 5. Google Scholar 7 : Radioimmunoscintigraphy with111 Indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Urol1994; 152: 1490. Link, Google Scholar 8 : Two different lymph node metastatic patterns of prostate cancer. Cancer1990; 65: 1843. Google Scholar From the Divisions of Urology and Nuclear Medicine, Southern Illinois University School of Medicine, Springfield, Illinois© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byPALAPATTU G and REITER R (2018) Monoclonal Antibody Therapy for Genitourinary Oncology: Promise for the FutureJournal of Urology, VOL. 168, NO. 6, (2615-2623), Online publication date: 1-Dec-2002. Volume 160Issue 6 Part 2December 1998Page: 2393-2395 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.Keywordsprostatic neoplasmsantibodiesradiotherapymonoclonalMetricsAuthor Information JOHN H. TEXTER More articles by this author CHARLES E. NEAL More articles by this author Expand All Advertisement PDF downloadLoading ...